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The birth of Henry Solomon Wellcome in 
1853 in a remote part of Wisconsin was 
ultimately a significant event for Brit-
ish science. The Wellcome Trust charity 
that resulted from the will he drew up in 
1932 funds a significant portion of bio-
medical research in the UK. This heavy-
weight funder, with an endowment of 
£13 billion, spends about £600 million 
each year on research in the UK; this 
is comparable to the £720 million spent 
annually by the UK’s Medical Research 
Council (MRC), the government arm of 
biomedical research. In contrast, in the 
US, the nonprofit philanthropic Howard 
Hughes Medical Institute (HHMI; http://
www.hhmi.org/) spent $730 million on 
research in 2009, a fraction of the $28 
billion spent by the US government-
funded National Institutes of Health. 
Given that the Wellcome Trust is a major 
funder of research in the UK and Ireland, 
scientists paid attention when the char-
ity announced late last year that it was 
changing its funding strategy (http://
www.wellcome.ac.uk/).
The Trust plans to end its traditional 
project and program grants this summer 
and to divert the money into new Investi-
gator Awards that will be flexible in length 
and scale and will focus on individual sci-
entists rather than projects. “Our awards 
will be anything from four years to seven, 
and we’ll provide people with a scale of 
support to really tackle important ques-
tions,” says Mark Walport, Director of 
the Wellcome Trust. But he is adamant 
that this is an evolution, not a revolu-
tion. “It is really taking our fellowship 
model and extending it to people who 
have salaried jobs,” he says. The Trust’s 
current fellowships fund scientists not 
directly employed by research institu-
tions or universities. “It has always been 
a bit illogical that the second you had a 
salaried position in a university, rather 
than having that very personal support 
[in fellowships], people go on to project 
grants and programme grants,” says 
Walport. He stresses that the change 
must also be seen in the context of the 
Trust’s overall portfolio. “Essentially we 
will have four types of grant. We will have 
our fellowships and Investigator Awards, 
our technology translation awards and 
our Strategic Awards.” The new Investi-
gator Awards will fund both new inves-
tigators and senior investigators with a 
maximum of £425,000 per year for up to 
7 years for each award. Applications will 
be accepted from October 1st this year, 
with the first awards to be announced in 
May 2011.
But the Wellcome’s change in strategy 
comes as the UK and Ireland face eco-
nomic woes, budget deficits, and gov-
ernment cuts. The UK general election 
last month gave the country a coalition 
government of Conservatives and Lib-
eral Democrats. Before the election, the 
Conservatives had stressed the impor-
tance of innovation, rather than basic sci-
ence, and their shadow science minister 
had said major cuts in the science bud-
get would be inevitable. Meanwhile, the 
Liberal Democrats had promised no cuts 
in science spending in their first year. 
However, with the European Commis-
sion warning that the UK budget deficit 
will reach 12% of GDP this year, topping 
the list of the 27 EU countries, the UK’s 
new coalition government has promised 
to reduce the deficit by cutting spend-
ing and not raising taxes, with £6 billion 
in cuts to non-front-line services within 
the financial year 2010–2011. Although 
certain areas such as health may be 
spared cuts, it is doubtful that science 
will be so lucky. “People are worried that 
there may be a significant lack of growth 
in science funding coming and we are in 
for a very tough time,” says Ray Dolan, 
Director of the Wellcome Trust Centre 
for Neuroimaging at University College, 
London. Walport is positive about the UK 
as an environment for medical research 
but says, “clearly there are economic 
threats to research, but hopefully the 
new government will recognise that the 
future prosperity of the UK depends 
on the fruits of our intellectual endeav-
ours. Around the world, countries that 
are good at science are increasing their 
investment, not cutting it.”
Meanwhile Irish scientists, who are 
eligible to apply for Wellcome Trust sup-
port, are already facing steep cuts as the 
government has begun to tackle its bal-
looning deficit by cutting €10 billion from 
across all government sectors. Science 
Foundation Ireland (SFI) (http://www.sfi.
ie/), a government-funded organization 
that in 2009 handed out €170 million in 
research grants, was dealt an 11% cut 
in its allocation for 2010. SFI admits that 
it will be tough to retain the infrastruc-
ture and people it has built up since its 
launch a decade ago. Ireland’s Health 
Research Board, which spends €50 
million on research annually, is shift-
ing its emphasis from basic biomedical 
research to clinical and health services 
research, placing further demands on 
SFI and the Wellcome Trust.
Given the economic uncertainty, 
the Trust’s change in funding strategy 
has met with a mixed reception. Susan 
Greenfield, professor of pharmacology 
at the University of Oxford, applauds the 
decision to fund by person rather than 
project. “However, I do have serious 
worries about abolishing project grants 
altogether,” says Greenfield, who recalls 
the independence she achieved when 
she received her first small project grant. 
Patricia Johnson at Dublin City Uni-
versity, who holds a Wellcome project 
grant, says these grants will be missed 
and is doubtful her present work would 
have been funded under the new regime. 
“If someone doesn’t have an exemplary 
publication record, it doesn’t mean that 
their idea isn’t valid and important and 
useful,” she says. Her concern is not 
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“about the scheme itself, but the phas-
ing out of project grants.” Greenfield 
also points out that “You are taking a 
huge gamble if you concentrate funds 
onto fewer people that they are indeed 
the right people at the right time … I’m 
also a bit concerned about backing win-
ners because you don’t know who the 
winners necessarily are in research,” she 
adds. People can fade or be late devel-
opers or have just one amazing idea.
The best way for the Trust to tackle 
ambitious problems in medical research 
is to pick exciting scientists, says Adrian 
Bird at the Wellcome Trust Centre for Cell 
Biology in Edinburgh, who is also a Trust 
governor. “The total number of individu-
als receiving Wellcome Trust funding in 
the UK is likely to fall,” he admits, but the 
Trust’s job “is not to necessarily maintain 
the health of the scientific enterprise in 
the UK; its mission is more specific. It 
wants to fund research that is going to 
advance human health and it will choose 
whatever way is most likely to succeed.”
Weighing up the pros and cons of 
the new scheme, Ian Robertson of Trin-
ity College Dublin says: “It will be more 
difficult for some people to get grants, 
but the chance of getting major break-
throughs by allowing people to pursue 
a more flexible program of research 
probably outweighs the disadvantages.” 
One potential downside, however, is 
that larger research groups will gobble 
up more of the pie. Robertson agrees: 
“That is a disadvantage, but that pro-
cess has been happening under the 
existing system, and I’m not sure it is 
going to change that.” The most extreme 
view is that the move will help phase out 
smaller labs altogether. One researcher 
in a smaller lab commented: “If small 
labs are phased out, even the larger 
will suffer, even though they will get the 
money. It is against the spirit of collabo-
ration and support.” However, Bird says 
the idea that large groups will be favored 
is just false. “The assumption that sci-
ence gets bigger and bigger in order to 
solve larger problems is not necessarily 
correct. I personally don’t believe there 
is any need for the size of groups to 
increase.”
Kingston Mills at Trinity College Dub-
lin sees the new Investigator Awards as 
a strategic move. “They are looking at 
what is happening in the States and see-
ing that the US is still ahead of Europe 
in terms of research output. There is 
a feeling that by giving more funding 
to a smaller number of good people 
the returns will be greater.” The move 
also dovetails with Wellcome’s recently 
announced Strategic Plan for 2010 to 
2020, which acknowledges that scien-
tific discoveries take time, so research-
ers should be given the time and 
resources to find answers. The Strategic 
Plan will focus Wellcome’s resources on 
five major research areas—genetics and 
genomics, the brain, infectious disease, 
aging and chronic disease, and nutrition 
and the environment.
Some say that the Trust’s switch from 
projects to people mirrors the successful 
model of HHMI in the US. “It is very much 
following the Howard Hughes model of 
extreme excellence, giving scientists 
the freedom and flexibility to explore the 
best ideas,” says one senior UK scientist, 
who asked not to be named. “The How-
ard Hughes is the icing on the cake of a 
very well funded enterprise in American 
research, but in the UK, the Wellcome 
Trust has been, together with the MRC, 
the bulwark keeping biomedical research 
alive.” He says his institution is likely to 
do better under the new scheme, and it 
might be the right way to get the best sci-
ence done. But he adds: “There’s a con-
cern I hear expressed as ‘To those that 
hath, shall be given.’” Some accuse the 
Trust of elitism, saying that this switch to 
HHMI’s model reflects a desire for Nobel 
prizes, but the Trust denies this. And 
HHMI’s President, Robert Tjian, points 
out that it is through their selection pro-
cess that they ended up with Nobel lau-
reates. “We had no idea they were going 
to be the elite. We are looking for people 
who are doing great science,” he says. 
“We tend to go for people, quite frankly, 
because it is easier to judge people than 
it is to judge projects.”
But there are advantages to Well-
come’s new scheme in the form of the 
application itself, which is much shorter 
than more traditional grant applications. 
“We will be asking people to articulate a 
vision, a place they want to go, how they 
will get there and why they are the ones 
who will be successful,” explains Alan 
Schafer, the Trust’s Director of Science 
Funding. Flexibility and vision are the 
watchwords. “We want people to come 
in and say this is how much it is going to 
cost and this is how long it will take,” he 
says. “What do you want to accomplish 
overall? Sure it has to be substantiated, 
but don’t tell me the restriction enzyme.”
An Expert Review Group, comprising 
scientists from the UK and overseas, will 
review proposals and select candidates, 
whose applications will then be peer 
reviewed; a shortlist of applicants will 
be invited for an interview. The personal 
interview has found favor with many. 
“I would love the opportunity to talk to 
somebody face to face. Sometimes you 
get reviews back and don’t have any 
recourse. Perhaps you didn’t put some-
thing clearly enough or maybe a reviewer 
picks up on something slight that you 
could easily defend,” says Johnson. And 
Schafer notes that, given his experience 
on fellowship committees, it is not simply 
people who interview well who are suc-
cessful, there has to be substance too. 
Dolan is confident that the interview will 
not be an obstacle for young research-
ers: A younger investigator “might feel 
intimidated by the fact that they don’t 
have a long track record, but any fund-
ing system has to be cognizant of that. 
These are the young people who are 
going to be the future backbone of Brit-
ish science,” he says.
Indeed the Trust is anxious to reassure 
young scientists that they will not be dis-
advantaged by the switch from projects 
to people. “We will very deliberately have 
investigator grants for people within the 
first few years of their salaried positions, 
because it is important to compare 
apples with apples,” explains Walport. 
Schafer concurs: “We have a concern 
that this program could either be per-
ceived or end up favoring people who are 
later in their career, who have the Cell, 
Science, Nature papers,” he says. “We 
love those sorts of researchers. How-
ever, we also strongly want to be funding 
people to reach their potential instead 
of continuing to build on their achieve-
ments.” The Trust will keep in place its 
4 year PhD studentship programmes, as 
well as its 4 year fellowships for people 
within a year of completing their PhD.
Walport feels that reaction to the 
change overall has been favorable. 
“There is a certain amount of excitement; 
there’s a certain amount of apprehen-
sion. But the best scientists recognize 
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that this is going to offer them tremen-
dous opportunities,” says Walport. “One 
of the defects of the project grant system 
is that people are expected to know what 
they are going to discover. If you know 
what you are going to discover, it is prob-
ably not worth discovering,” he notes. 
“When you talk to the scientific com-
munity and scientists individually, they 
complain about the short-term nature 
of the project grant, about the fact that 
it limits ambition, and yet, on the other 
hand, people are remarkably conserva-
tive about the funding models.” Peter 
Donnelly, Director of the Wellcome Trust 
Centre for Human Genetics in Oxford, 
says of the Trust’s change in direction 
that it is an interesting move but is more 
circumspect regarding its outcome. 
“Funding good people with more secure 
and longer term funding makes a lot of 
sense,” he says. “Exactly what the con-
sequences will be in practice is a bit hard 
to predict.”
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